Working... Menu
Trial record 1 of 57 for:    Romidepsin | Phase 2
Previous Study | Return to List | Next Study

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients (FIL_GEMRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01822886
Recruitment Status : Completed
First Posted : April 2, 2013
Last Update Posted : August 31, 2018
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS